29 January 2020
Our Ref: MW/AW/FOI 6727

Dear Applicant,


Further to your request for information received 16 January 2020 please find the Trust’s response below.

On 1st October 2019, Liverpool University Hospitals NHS Foundation Trust was created, through the merger of Aintree University Hospital NHS Foundation Trust and Royal Liverpool and Broadgreen University Hospitals NHS Trust. Therefore, this response is for all sites.

**Response from Liverpool University Hospitals NHS Foundation Trust:**

1. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
   - Aflibercept
   - Bevacizumab
   - Capecitabine
   - CAPIRI
   - CAPOX
   - Cetuximab not in combination with FOLFIRI or FOLFOX
   - Cetuximab in combination with FOLFIRI
   - Cetuximab in combination with FOLFOX
   - Irinotecan
   - FOLFIRI
   - FOLFOX
   - Oxaliplatin
   - Panitumumab not in combination with FOLFIRI or FOLFOX
   - Panitumumab in combination with FOLFIRI
   - Panitumumab in combination with FOLFOX
   - Nivolumab
   - Raltitrexed
   - Ramucirumab
   - Regorafenib
   - Sorafenib
   - 5FU only
   - Tegafur Uracil + 5FU
   - Trifluridine–tipiracil
   - XELOX
   - Other

   • Please see our response to question 2 below.
2. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
Sunitinib
Avelumab + Axitinib
Aximitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib

- The Liverpool University Hospitals NHS Foundation Trust does not treat patients for the above diseases with the above listed medications. Under Section 16 (duty to provide advice and assistance) and in the interests of openness and transparency, we suggest redirecting this request to the Clatterbridge Cancer Centre NHS Foundation Trust. You can make a request under Freedom of Information Act 2000 by emailing: ccf-tr.foi@nhs.net

3. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

- There are currently no trials being undertaken at the Liverpool University Hospitals NHS Foundation Trust for the treatment of renal cell cancer patients.

If you have any queries about this response or wish to discuss your request further please contact the Freedom of Information Team.

**Right to Review**

If you are dissatisfied with the handling of your request you have the right to ask for an internal review.
To do this, please email FOIRequests@liverpoolft.nhs.uk and quote the reference number above.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner for a decision. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by the Trust. The Information Commissioner can be contacted at: The Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Kind Regards

Freedom of Information Team
Liverpool University Hospitals NHS Foundation Trust
FOIRequests@liverpoolft.nhs.uk

Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.
Liverpool University Hospital NHS Foundation Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Re-use of Public Sector Information

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.